Biotech ER

Breaking into Biotech Equity Research (ER) without a STEM background is challenging but not impossible. Based on the most helpful WSO content, here are some key insights:

1. Conventional Pathways:

   • Most professionals in Biotech ER typically have advanced degrees like PhDs or MDs in life sciences. This is because the role often requires a deep understanding of scientific concepts, clinical trials, and drug development processes.

2. Alternative Routes:

   • Applicants without a doctoral degree but with experience in Healthcare Equity Research or Healthcare Investment Banking are also considered. Strong analytical skills, the ability to conduct primary research, and excellent communication skills are critical.
   • Networking is a powerful tool. Some individuals have successfully transitioned into Biotech ER by leveraging connections and demonstrating their ability to learn and adapt quickly.

3. Key Requirements:

   • A willingness to obtain certifications like Series 7, 63, 86, and 87 is often necessary.
   • Exceptional work ethic, attention to detail, and a desire to learn about the biotechnology industry are essential traits.

4. Challenges Without STEM:

   • Without a STEM background, you may lack the scientific intuition that comes from years of lab work or academic study. However, diligence, self-directed learning, and the ability to ask the right questions can help bridge this gap.

5. Success Stories:

   • There are examples of finance professionals with no science background excelling in biotech by conducting thorough due diligence and consulting with experts. This highlights that while a STEM background is advantageous, it is not an absolute requirement.

In summary, while a STEM background or advanced degree is the norm, breaking into Biotech ER without one is possible with the right experience, skills, and networking efforts.

Sources: Biotech equity research possible with ZERO finance experience?, Biotech finance: from IB to VC / HF to funded startup, Biotech finance part 2: valuation methodologies and modeling considerations, Biotech finance part 2: valuation methodologies and modeling considerations, Why are you still trying to break into equity research?